lenvatinib诱导的血压升高是肝细胞癌患者预后的有利因素吗？

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research Pub Date : 2025-03-26 DOI:10.1038/s41440-025-02197-w

Satoshi Kidoguchi

引用次数: 0

摘要

Lenvatinib是一种多酪氨酸激酶抑制剂，被批准用于治疗多种癌症类型，可诱导高血压，可作为肝细胞癌患者预后指标。进一步研究抗肿瘤药物引起的血压升高的机制是必要的，患者应该由一个多学科的“肿瘤-高血压”团队来管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?

Lenvatinib, a multi-tyrosine kinase inhibitor approved for the treatment of multiple cancer types, can induce hypertension, which can be a prognostic indicator in patients with hepatocellular carcinoma. Further research into the mechanism of anticancer drug-induced blood pressure elevation is necessary and patients should be managed by a multi-disciplinary "Onco-Hypertension" team.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hypertension Research 医学-外周血管病

CiteScore

7.40

自引率

16.70%

发文量

249

审稿时长

3-8 weeks

期刊介绍： Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.